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ABSTRACT
Age-related macular degeneration (AMD) is a leading cause of blindness 
worldwide affecting individuals over the age of 50. The neovascular form (NV 
AMD) is characterized by choroidal neovascularization (CNV) and responsible for 
the majority of central vision impairment. Using non-biased microRNA arrays and 
individual TaqMan qPCRs, we profiled miRNAs in the vitreous humour and plasma of 
patients with NV AMD. We identified a disease-associated increase in miR-146a and 
a decrease in miR-106b and miR-152 in the vitreous humour which was reproducible 
in plasma. Moreover, miR-146a/miR-106b ratios discriminated patients with NV 
AMD with an area under the Receiver Operating Characteristic curve (ROC AUC) of 
0,977 in vitreous humour and 0,915 in plasma suggesting potential for a blood-based 
diagnostic. Furthermore, using the AMD Gene Consortium (AGC) we mapped a NV 
AMD-associated SNP (rs1063320) in a binding site for miR-152-3p in the HLA-G gene. 
The relationship between our detected miRNAs and NV AMD related genes was also 
investigated using gene sets derived from the Ingenuity Pathway Analysis (IPA). To 
our knowledge, our study is the first to correlate vitreal and plasma miRNA signatures 
with NV AMD, highlighting potential future worth as biomarkers and providing insight 
on NV AMD pathogenesis.
INTRODUCTION
Age-related macular degeneration (AMD) is a 
progressive retinal pathology affecting the elderly. It is 
estimated that over 10 million Americans have a form of 
AMD and this figure is predicted to triple in the next 25 
years [1, 2]. Consequently, AMD is the most important 
cause of vision loss in individuals over 50 and by some 
estimates affects more than 25% of the population over 
80 years of age [3, 4]. There are two major clinical 
subtypes of sight-threatening AMD: dry atrophic AMD 
and wet exudative AMD [5]. Dry AMD is characterized 
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by geographic atrophy while the neovascular form of 
AMD (NV AMD), by the growth of abnormal leaky 
choroidal vessels into the retina [6]. The exudative form is 
responsible for the majority of central vision impairment 
and legal blindness and accounts for 90% of clinical cases 
with loss of sight [1].
While genome-wide association (GWA) studies have 
successfully identified genetic links to AMD, there remains 
a void in our understanding of how extrinsic modulators 
of gene expression impact disease outcome. In this regard, 
there has been growing interest over the last decade in 
small non-coding RNAs called microRNAs (miRNAs) 
and their role as potent suppressor of gene expression in 
health and disease [7]. It is current thought that miRNAs 
control the expression of over a third of human genes 
and are key regulators of every primary biological 
process including angiogenesis, inflammation, cellular 
proliferation, apoptosis, differentiation, organogenesis and 
many more [8-11]. To date, more than 2000 of these small 
RNAs of about 20 nucleotides have been identified in 
humans and they are highly conserved throughout species 
[7]. Interestingly, hundreds of small RNAs have been 
detected in a spectrum of body fluids such as blood, urine, 
vitreous humour, saliva, cerebrospinal fluid and more 
[12, 13]. Studies have shown that in addition to being 
detectable in blood cells, miRNAs circulate in secreted 
exosomes [14, 15], micro-vesicles [16], apoptotic bodies 
[17], bound to the AGO2 complex [18] and in lipoproteins 
[19]. Much like hormones, miRNAs are secreted and 
provide highly specific signatures for conditions ranging 
from kidney disease to cancer. Moreover, SNPs that can 
disrupt or enhance binding of miRNAs have been reported 
in microRNA binding sites (miRSNPs) in specific genes 
and polymorphisms in miRNA binding sites are currently 
being assessed as potential biomarkers in oncology [20]. 
Interestingly, several circulating miRNAs are involved in 
the regulation of angiogenic and inflammatory process that 
are at the center of AMD pathophysiology [11, 21]. 
In the present study, we profiled miRNAs in 
the vitreous humour and plasma of patients suffering 
from NV AMD and control patients with non-vascular 
ocular pathology. We were able to identify a differential 
expression profile for 3 miRNAs (miR-146a-5p, miR-
106b-5p, and miR-152-3p) in vitreous humour and 
validated this profile in circulation. We applied our 
findings on differential miRNA expression patterns to 
results from the AMD Gene Consortium (AGC) [22] 
and searched for NV AMD-associated DNA sequence 
variants resident in genomic regions encoding our three 
NV AMD-associated miRNAs and 484 associated binding 
motifs. We identified a NV AMD-associated sequence 
variant in HLA-G (rs1063320) that overlapped a genomic 
region with the capacity to encode a binding motif for 
hsa-miR-152-3p. In addition, numerous sequence variants 
resident in genes encoding products that are regulated by 
miR-146a-5p, miR-106b-5p and miR-152-3p are strongly 
associated with NV AMD. To our knowledge, this study is 
the first to identify miRNA signatures in patients suffering 
from NV AMD and highlights their potential future 
applications as diagnostic or prognostic tools.
RESULTS
Profiling miRNAs in vitreous humour reveals 
distinct expression patterns in patients with 
NV AMD compared to control patients with 
nonvascular ocular pathology
All AMD patients undergoing miRNA profiling 
were diagnosed with pronounced CNV by Optical 
Coherence Tomography (OCT) (Figure 1A and 1B, 
right panels) and fundus image analysis (Figure 1A and 
1B, left panel) before collection of vitreous humour. 
Patient characteristics are outlined in Tables 1 and 2. The 
vitreous humour of patients with nonvascular pathology 
(epiretinal membrane or macular hole) was used as 
a control. Large scale miRNA profiling using micro 
arrays (panel A: Applied Biosystems) was conducted 
on the vitreous humour of 4 patients with NV AMD 
and 2 control patients (work flow in Figure 1C). After 
analyzing individual amplification curves, 26 miRNAs had 
detectable amplification profiles (Figure 1D-1F). Of these, 
5 miRNAs showed disease-specific expression profiles 
after weighted mean normalization and determination 
of qPCR efficiency (Figure 1E) [23, 24] where qPCR 
efficiencies were calculated with raw fluorescence values 
and gave a more precise estimation of the quantity of 
miRNA in the sample. This additional analysis is useful to 
compare qPCR reactions with similar efficiency and avoid 
a batch effect between different plates and qPCR reactions 
[25]. We applied a cut-off of 80% efficiency and excluded 
results under this limit. Specifically, vitreous from patients 
with NV AMD showed an increase in the levels of miR-
548a (3.58 fold; P= 0.04) and miR-146a-5p (6.2 fold; 
P= 0.020) and a decrease for miR-106b (-5,73 fold; P= 
0.010), miR-152 (-5,63 fold; P= 0.046) and miR-205 
(-3.56 fold; P= 0.047) (Figure 1G) Together, these results 
offer novel evidence for differential miRNA expression in 
the vitreous of patients with exudative AMD, suggestive 
of either their implication in AMD pathology or being 
produced as a consequence of NV AMD.
Validation of NV AMD-associated miRNAs in 
vitreous humour of larger cohorts
In order to ascertain validity of the data obtained 
by micro arrays, we evaluated miRNA expression profiles 
by individual TaqMan micro in a larger cohort of patients 
(Table 1). As housekeeping miRNAs are not established 
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Figure 1: Human vitreous humour profiling identifies 5 potential miRNAs deregulated in NV AMD. Vitreous humour 
biopsies were performed on patients with non-vascular ocular pathology (Epiretinal membrane or macular hole) A. or patients with 
exudative AMD (white arrow points to CNV) B. C. A work flow describing the process from patient to miRNA micro arrays. Initial pilot 
screen was on two samples from control patients and 4 samples from the AMD group. D. Complete heat map of miRNAs detected by micro 
arrays. E. Heatmap representing miRNAs identified to have a significant difference (P < 0.05). F. Gray arrow defines steps of exclusion. 
G. Histogram representation of 5 miRNAs deregulated in AMD compared to the level detected in control group (expressed as log2 (qPCR 
efficiency)-∆Ct fold change relative to control).
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Table 1 : Patient baseline statistics
Table 2: Clinical characteristics of patients having undergone vitreous biopsy
Vitreous and plasma from a cohort of 13 patients with non-vascular retinal pathology (control 
group) and 13 patients with NV AMD. AMD: Age related Macular Degeneration with CNV (choroid 
neovascularization); naive: before anti-VEGF treatment; NA: not applicable; MH: Macular Hole; CAT: 
Catheter; ERM: epiretinal membrane; OCT: Optical Coherence Tomography. Analysis by microarray 
and/or qPCR (individual TaqMan miRNA assay).
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for vitreous humour and qPCR array data did not yield 
a candidate, we normalized using the weighted mean of 
qPCRs. Results were normalized and presented as log2-
transformed qPCR fold-change (Figure 2). In addition, we 
included corresponding fold change values in linear scale 
to appreciate the difference between groups. 
Consistent with micro array data, individual miRNA 
qPCRs confirmed an increase in levels in the vitreous 
humour of patients with NV AMD of miR-146a (Figure 
2A) by ~ 3 (3.02 ± 0.5830), and a decrease in levels of 
Figure 2: Validation of expression profiles for miR-146a, miR-106b and miR-152 in the vitreous humour of patients 
with NV AMD. Data are represented in log2 (qPCR efficiency)-∆∆Ct fold change relative to control in graphs. A. miR-146a increased by 
~ 3 (3.02 ± 0.5830) (corresponding log2 values: 2.02; ± 0.3587, P = 0.0043). B. Significantly decreased levels of miR-106b by ~4 (0.23  ± 
0.0797) (corresponding log2 values: -1.92 ± 0.3822, P = 0.003) and C. miR-152 by ~ 3 (0.33 ± 0.132) (corresponding log2 values: -2.63 ± 
0.8569, P = 0.0137) were detected in vitreous humour of patients with NV AMD. 
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miR-152 (Figure 2C) by ~ 3 (0.33 ± 0.132). Levels of miR-
106b also decreased (Figure 2B) by ~4 (0.23 ± 0.0797) in 
NV AMD patients where this miRNA was predominantly 
undetected (corresponding log2 values: miR-146A, 2.02 
± 0.3587; P = 0.0043; miR-106b, -1.92 ± 0.3822, P = 
0.003; miR152, -2.63 ± 0.8569, P = 0.0137). Conversely, 
the expression of miR-548a and miR-205 (both detected 
by micro array) did not vary significantly in the validation 
cohorts. Similar to array analysis, efficiency of qPCR 
reactions was calculated with raw fluorescence values to 
precisely estimate the amount of miRNAs in each sample 
and to compare samples with similar efficiencies [23, 24].
To determine if age was a confounding factor, 
we analyzed levels of miRNAs against patient age. No 
significant correlation was observed between individual 
age and the fold change of miRNAs (miR-146a r2 = 
0.1769, miR-106b r2 = 0.0314 and miR-152 r2 = 0.1926) 
supporting the idea that the observed signature of vitreous 
humour miRNAs was attributed to NV AMD.
AMD-specific expression of plasma miRNAs 
mirror levels found in vitreous humour
To determine if AMD-specific miRNA signatures 
can be obtained via less invasive routes, we profiled levels 
of miR-146a, miR-106b and miR-152 in plasma. miR-
16 was used as a reference as previously described [26]. 
Plasma samples were tested for hemolysis and samples 
with an index higher than 1 were excluded (Supplemental 
Figure 1A). With a cutoff of hemolysis index at 1, no 
correlation was observed between miR-16 (Supplemental 
Figure 1B) and the 3 investigated miRNAs between 
groups (Supplemental Figure 1C -1E). As for the vitreous 
humour, results were normalized and presented as log2-
transformed qPCR fold-change (Figure 3). Fold change 
values in linear scale are also presented. 
Similar to that observed in vitreous humour, miR-
146a was significantly increased (Figure 3A) by ~2.5 (2.57 
± 0.311) in the plasma of patients with NV AMD while 
miR-106b (Figure 3B) and miR-152 (Figure 3C) were 
respectively decreased by ~ 1.5 (0.65 ± 0.1281) and 1.7 
(0.58 ± 0.064) (corresponding log2 values: MiR-146-a, 
1.035 ± 0.312, P = 0.0388, miR106b, -0.81 ± 0.3366, P 
= 0.0301, miR-152, -0.71 ± 0.225, P = 0.0463). Similar 
magnitudes and expression profiles were obtained when 
miRNAs were normalized with weighted mean over miR-
16 (Supplemental Figure 2).
Similar to the vitreous humour, no significant 
correlation was drawn between patient age and levels of 
miRNAs (miR-146a r2 = 0.1787, miR-106b r2 = 0.1564 
and miR-152 r2 = 0.0243). Together, these results suggest 
that detection of plasma miRNAs mirrors profiles found in 
the vitreous humour and correlates with NV AMD.
Vitreous humour or plasma ratio of miR-146a/
miR-106b predicts NV AMD
Combinations of levels of different miRNAs 
can significantly augment the predictive value of these 
biomarkers [7]. We evaluated the potential of the miR-
146a/miR-106b ratio to identify NV AMD patients (Figure 
4). Our data demonstrated that ratios from both vitreous 
humour and plasma were significantly increased by ~10 
(10.35 ± 4.10, P = 0.016) and ~1.7 (1.68 ± 0.22, P = 
0.0072). We then assessed the diagnostic accuracy of these 
ratios as predictors of NV AMD. In this regard, Receiver 
Operating Characteristic (ROC) analysis is widely used to 
quantify how accurately a medical test can discriminate 
between a diseased and a non-diseased state. The resulting 
ROC curve is created by plotting true positive rate against 
false positive rate at different threshold settings. The area 
under the curve (AUC) then represents the probability that 
a random AMD patient is ranked as more likely to have 
AMD than a randomly chosen control patient. A maximal 
AUC value of 1 means that the test perfectly discriminates 
AMD and non-diseased patients.
The ROC AUC for miR-146a/miR-106b ratio was 
0,977 in the vitreous humour (Figure 4C: P = 0.0005 95% 
confidence interval 0.9205 to 1.034) and 0,914 in plasma 
(Figure 4D: P = 0.0186; 95% confidence interval 0.7346 
to 1.094). These results strongly underscore potential 
for plasma miR-146a/miR-106b ratios as a non-invasive 
biomarker for NV AMD.
Investigation of NV AMD-associated Single 
Nucleotide Polymorphisms (SNPs) in miR-146a-
5p, miR-106b-5p, and miR-152-3p binding sites
Dysregulation of miRNA expression is central to 
several human diseases. Moreover, mutations in miRNA 
binding sites leading to increased or decreased binding 
affinity can also contribute to pathophysiology. We filtered 
NV AMD-associated SNPs from the 77,000 person AMD 
Gene Consortium (AGC) cohort [22] to search for NV 
AMD-associated SNPs in the experimentally determined 
(see Methods and Table S1) target gene binding sites 
of miR-146a, miR-106b and miR-152. We identified 
a NV AMD-associated SNP in the 3’UTR of HLA-G 
gene, in a binding site for miR-152-3p (rs1063320). 
This SNP attained a P-value of 0.026 (Q-value = 0.116) 
for NV AMD relationship in the AGC and is found 
in chromosome 6 spanning nucleotide base positions 
29830959 to 29830978. This finding reinforces the 
involvement of miR-152 in AMD pathogenesis. Further 
work is needed to characterize the involvement of HLA-G 
in AMD progression and the impact of this SNP on miR-
152 affinity.
We next evaluated the relationship between our 
detected miRNAs and NV AMD related genes, using 
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Figure 3: Expression profiles of miRNAs in plasma mirror levels found in vitreous humour. Plasma collected from the same 
patients as vitreous humour profiled in figures 1 & 2. Data are represented in log2 (qPCR efficiency)-∆Ct fold change relative to control in 
graphics A. A significant increase by ~2.5 (2.57 ± 0.311) (corresponding log2 values: 1.035 ± 0.312, P = 0.0388) was detected for miR-146a 
in plasma from patients with NV AMD. Significant decreases in  B. miR-106b by ~1.5 (0.65 ± 0.1281) (corresponding log2 values: -0.81  ± 
0.3366, p = 0.0301) and C. in miR-152 by ~1.7 (0.58 ±  0.064) (corresponding log2 values: -0.71 ± 0.225, P = 0.0463) were also detected 
in the plasma of patients with NV AMD. 
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gene sets derived from the Ingenuity Pathway Analysis 
(IPA). The IPA Knowledge Base provides annotations 
on miRNA-gene relationships; we used these gene sets 
to filter the AGC findings on NV AMD-associated SNPs 
resident in genes associated with miR-146a-5p, miR-106b-
5p, and miR-152-3p. Table S2 contains the gene lists and 
functional annotations for each miRNA. 
Table S3 contains NV AMD-SNP findings for all 
SNPs present in each NV AMD-related gene (significant 
at P < 0.005) with a binding site for any of the 3 identified 
miRs. The IPA gene set includes 57 genes containing 
miR-146a-5p binding sites. Six of these genes (CFH, 
NFKB1, LTB, MCPH1, COL13A1, and MMP9) carry 
SNPs associated with NV AMD at P- values < 0.005 in 
the AGC - we computed Q-values to determine that NV 
AMD-associated sequence variants in each of these miR-
146a-5p gene binding sequences showed an expected 
proportion of false positives among significant tests that 
was less than 2% (Table S3). There were 19 genes in the 
IPA gene set containing binding sites for miR-106b-5p. Of 
these, 1 gene (SMAD3) contains SNPs associated with NV 
AMD at P-values < 0.005 in the AGC cohort. Q-values 
for the strongest relationships with NV AMD were less 
than 0.035, indicating that the expected proportion of 
false positives among significant tests was less than 3.5% 
(Table S3). Finally, there were 10 genes with miR-152-
3p binding sites in the IPA gene set. Beside the SNP in 
the HLA-G binding site, none of these genes in the AGC 
cohort contained SNPs associated with NV AMD at 
P-values < 0.005. Supplemental Figure 3 contains plots 
Figure 4: The miR-146a/miR-106b ratio in vitreous humour and blood is predictive of NV AMD. MiR-146a/miR-106b 
fold change ratio was calculated for AMD and control for A. vitreous humour (10.35 ± 4.10, P = 0.016) and C. plasma (1.68 ± 0.22, P 
= 0.0072). The area under the Receiver Operating Characteristic curve (ROC AUC) for miR-146a/miR-106b ratio was B) 0,977 in the 
vitreous humour (P = 0.0005; 95% confidence interval 0.9205 to 1.034) and B. 0,914 in plasma (P = 0.0186; 95% confidence interval 
0.7346 to 1.094).
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of predicted miR-146a-5p, miR-106b-5p, and miR-152-
3p binding sites in genes in the chromosomal position of 
AGC findings on NV AMD.
DISCUSSION
The prevalence of AMD in developed countries will 
continue to rise dramatically with the aging population 
[4, 6, 27]. To our knowledge, the present study is the 
first to profile miRNAs in human vitreous humour from 
patients with NV AMD. We used a bilateral approach 
where we first investigated miRNA signatures in vitreous 
humour and correlated the identified miRNAs with 
plasma levels in corresponding patients. Specific miRNA 
signatures in vitreous humour of patients with NV AMD 
lead us to identify three miRNAs (miR-146a, miR-106b 
and miR-152) that vary with disease (not with age) and 
have described roles in inflammation and angiogenesis. 
Secondly, using a GWA study we identified miRSNPs 
located in binding sites in genes associated with CNV 
phenotypes in AMD for these three miRNAs. DNA 
sequence variants found in miRNA binding sites could 
increase or decrease their binding and hence influence 
their function as translation regulators.
The presence of miRNAs in human vitreous 
humour may be important both in further understanding 
AMD pathogenesis and may provide insight on systemic 
biomarkers for AMD diagnostic. Of the 3 miRNAs 
identified, only one (miR-146a) was significantly 
increased and 2 decreased (miR-106b and miR-152) in NV 
AMD. Our results suggest a 3.0 fold increase in miR-146a 
in the vitreous humour of patients with NV AMD. In line 
with our findings, Lukiw et al. showed a 3-fold increase 
of miR-146a in the retina of patients with AMD [28]. 
Induction of miR-146a may be a protective mechanism 
that dampens innate immunity [29, 30]. MiR-146a has 
been reported to be induced by lipopolysaccharide (LPS), 
as well as by inflammatory cytokines IL-1β and TNFα 
[29, 31, 32] and has the ability to influence inflammatory 
cascades by interfering with IRAK and TRAF-6 [29, 33] 
as well as by directly down-regulating IL-6 [34]. Both 
IL-1β and IL-6 are associated with progression of CNV 
[33, 35], hence, miR-146a may be a protective regulator 
of inflammation in NV AMD. Finally, it is notable that 
the mature hsa-miR-146a-5p miRNA has been shown to 
bind the CFH gene in human neural [36, 37] and vascular 
endothelial cells [38].
Conversely, the detected reduction of miR-106b and 
miR-152 in the vitreous humour may exacerbate CNV 
given that miR-106b can decrease VEGF-A expression 
[39, 40]. In this line, a recent study implicated miR-106b 
in post-ischemic neovascularization in mice [41] via miR-
106b-dependant regulation of IL-8 [42, 43]. Similarly, 
the significant decrease of miR-152 may aggravate CNV 
by allowing angiogenic factors involved in AMD such as 
Fibroblast growth factor 2 (FGF2) to rise [44]. The tandem 
dysregulation of miR-106b and miR-152 could therefore 
contribute to increasing the burden of pro-angiogenic 
factors such as VEGF, FGF2 and IL-8 in the vitreous 
humour/retina, yielding an environment conducive to 
propagation of CNV [45].
Noninvasive biomarkers are still lacking for early 
detection of AMD. Profiling of miRNAs in body fluids 
such as blood shows promises for diagnostic, follow up 
and prognostic of human diseases [10]. Having for main 
goal to identify circulating miRNAs specific to AMD, 
we chose to first profile vitreous humour of patients with 
AMD. While Grassman et al. and Szermraj et al. both 
reported AMD-specific miRNA profiles in blood; our 
study was designed to correlate vitreous humour and 
blood miRNAs [46, 47]. When compared together, best 
hits for AMD-specific miRNAs in blood do not replicate 
between studies. However, it is worth mentioning that 
Szemraj et al. also reported an increase for miR-146a in 
the blood of their AMD cohort. Our profiling strategy 
initially called for identification of prospective miRNAs 
in vitreous humour and then used different analytical 
strategies that can potentially explain discrepancies 
between studies. This includes the matrix used, methods 
of RNA isolation, large scale profiling technologies and 
more [10]. In order to usefully translate our finding to a 
diagnostic test, signatures of circulating miRNAs must be 
established early in the disease process or ideally prior to 
onset. A non-invasive and predictive marker could be of 
interest considering the fact that lifestyle modifications 
(diet, smoking, obesity, etc.) can influence development of 
AMD. Future studies will need to be designed to address 
this point. 
To further investigate the potential involvement of 
miR-146a, miR-106b and miR-152 in AMD pathogenesis, 
we used experimentally validated miRNA targets to filter 
specific NV AMD associated loci in the AGC. The value 
of our findings on the residence of a NV-AMD-associated 
SNP in a hsa-miR-152-3p target-encoding site is to guide 
future work, with a possible focus on HLA-G. However, 
the 3 million AGC probe feature set contained less than 
5% of sequence variants within putative miR-146a-5p, 
miR-106b-5p and miR-152-3p predicted binding sites 
limiting the coverage of our analysis. To overcome this 
limitation, we further evaluated the relationship between 
our detected miRNAs and NV AMD related genes, using 
gene sets derived from the Ingenuity Pathway Analysis 
(IPA). Interestingly, 10% of hsa-miR-146a-5p targets also 
had AMD associated sequence variants with P-values < 
0.005 and false discovery rates < 1.5%.
Our study provides the first evidence that a specific 
miRNA signature is found both in the vitreous humour 
and plasma of patients with exudative AMD. As such, 
it offers proof-of-concept that miRNAs in systemic 
circulation may potentially be biomarkers for AMD and 
provides novel insight into miRNA-driven pathogenesis. 
Moreover, analysis of specificity and sensitivity (ROC 
Oncotarget19180www.impactjournals.com/oncotarget
curves) of the ratio between miR146a/106b suggests their 
potential for plasma-based biomarkers of NV AMD. In 
addition, detection of SNPs located in miRNA binding 
sites may be predictive of disease development. From a 
therapeutic perspective, miRNAs are endogenous multi-
target molecules and hence can be harnessed to modify 
disease outcome. They fill the growing interest in drug 
design for multi-target drugs. Generating synthetic 
therapeutic miRNAs or antagomirs is cost-effective and 
easy to produce and clinical trials are currently underway 
using inhibitors or synthetic mimics of miRNAs [21, 
48]. Therapeutic miRNAs may also influence the effects 
of prospective treatments for AMD such as Rapamycin 
(inhibitor of mTOR) [49] which has been suggested to 
decrease symptoms of AMD [50-53]. Taken together, 
identifying specific miRNA biomarkers for AMD would 
provide an invaluable tool for early intervention and 
disease modification. Therapeutic modulation of miRNAs 
may provide an alternative and may significantly reduce 
costs and toxicity of current anti-VEGF biologics and 
offer new therapeutic avenues to supplement the current 
options used to manage CNV.
MATERIALS AND METHODS
Vitreous humour sample and blood collection
All patients previously diagnosed with Wet AMD 
were followed and operated by a single vitreoretinal 
surgeon (F.A. Rezende). Control patients underwent 
surgical treatment for nonvascular pathology (epiretinal 
membrane or macular hole) by the same surgeon. In 
an operating room setting, patients underwent surgery 
under local retro/peribulbar anesthesia. A 5% povidone-
iodine solution was used to clean the periocular skin, and 
topical instillation into the eye and within the cul-de-
sac was left in place for 5 minutes. Three-port25-gauge 
trans conjunctival pars plana vitrectomy was performed 
through 25-gauge valved cannulas (Alcon). Under 
microscope visualization using a wide-angle viewing 
system (Resight, Zeiss), undiluted vitreous humour was 
collected with a 25-gauge vitrector. Vitreous humour was 
aliquoted in sterilized tubes and directly frozen on dry 
ice. Blood collection had been proceeding before solutes 
(IV) installation and vitreous humour biopsy. Blood was 
collected in tube containing 7.2 mg of K2 EDTA tube 
(purple). To collect plasma, blood was centrifuged for 10 
min at 1500 X g RPM. The plasma was transferred in new 
tubes and immediately frozen at -80oC.
miRNA array and microRNA extraction
Total RNA was isolated from vitreous humour 
samples by using TRIzol® Reagent (Invitrogen) in 
accordance with the manufacturer’s instructions. Equal 
volumes of 50µl of vitreous humour were used for miRNA 
extraction using 50µl of TRIzol® and 1µl of 20mg/ml of 
glycogen was added to increase the extraction specificity. 
Total RNA was eluted in 20µl of DEPC water. Total 
RNA samples of 2 controls and 4 wet AMD patients 
were shipped to IRIC’s genomic platform (Université 
de Montréal) to process the Human MicroRNA Card 
A v2 (Life Technologies). Retrotranscription (RT) 
was processed with the Megaplex™ RT for TaqMan® 
MicroRNA Assays (Human Pool A), followed by 
microRNA pre-amplification with the Megaplex™ 
PreAmp primers kit for TaqMan® MicroRNA Assays 
(Human Pool A) and the qPCR array assay (Human Card 
A including detection of 384 microRNAs and endogenous 
controls). A plate with ultrapure water was processed as 
negative control for primer dimerization detetection.
Individual qPCR validation
MicroRNAs from 50µl of vitreous humour or 
plasma were extracted with the TaqMan® miRNA ABC 
magnetic kit (Anti-miRNA Bead Capture for Human 
Panel A) by following instructions supplied by Life 
Technologies. Elution was done in 50µl and 100µl for 
vitreous humour and plasma respectively. RT and pre-
amplifications were processed as indicated in the protocol 
for creating custom RT and pre-amplification pools using 
20X TaqMan® MicroRNA Assays from Life Technologies. 
5µl of RT and qPCR primers from each TaqMan® 
MicroRNA Assays (miR-205, miR-106b, miR-146a, 
miR-152, and miR-548a) were pooled in a total volume of 
500µl TE buffer pH 8.0. 3µl of extracted microRNA was 
used to for the TaqMan® MicroRNA Reverse Transcription 
Kit (Life Technologies), 2.5µl of RT product was used 
for pre-amplification was assessed with 12 cycles as 
recommended in the Life Technologies protocol. Total 
volume (25µl) of pre-amplification product was diluted 
with 175µl of 0.1X TE buffer, pH 8.0. 2µl of the dilution 
was used as template in a total volume of 10µl of 20X 
TaqMan® MicroRNA Assay for each miRNA identified 
in the array (miR-205, miR-106b, miR-146a, miR-152, 
and miR-548a). The same strategy was were processed 
plasma samples. qPCRs were processed 3 to 4 times to 
avoid technical variation.
Normalization and statistical analysis
Realtime PCR gives expression levels of the gene/
miR as a threshold cycle (Ct) (inversely proportional 
to relative expression of target gene/miR). According 
to Taqman protocol, 40 cycles were considered as the 
detection threshold, above which miRs were considered 
as undetectable.
In order to normalize miRNA data and calculate fold 
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changes of each miRNA, ΔCt values were calculated by 
subtracting the Ct value of the endogenous control from 
the Ct of the target. However, except for plasma samples 
where miR16 is recognized as an endogenous control, 
at present there is no consensus concerning suitable 
miR endogenous control miR. To minimize systematic 
technical or experimental variation in vitreous humour 
samples, we opted here for a method considering all miR 
(miR16, miR106b, miR146a and miR152) as endogenous 
controls, also called weighted normalization, as follow:
with n corresponding to the number of genes 
(miRNAs), j to miRNAs, i to sample and wmp to the 
weighted mean power.
Technically, this miR Ct0 average was used as 
endogenous reference, for each sample.
ΔCt = CtmiR - Ct0
The ΔΔCt was then calculated by subtracting the 
ΔCt average of control patients from AMD patient.
ΔΔCt = ΔCtAMD - ΔCt control
Fold change (FC) was calculated using the 
following formula 2-∆∆CT , where the value 2 represents a 
theorical micro efficiency of 100%. For more accuracy, 
we evaluated micro array and TaqMan individual qPCR 
efficiency with free online software QPCR, which 
calulated 85% for the qPCR array (1,7) and 88% for 
indivivual qPCR (1,75).
FC = Efficiency-ΔΔCt
For performing T-statistics, variance should be 
normally distributed (bell curve); a log2 transformation 
was then applied to fold change values.
Log-transformed data = Log (Fold change; 2)
Log-transformed data were finally median-centered 
(average log-transformed controls then equaled 0).
Graphical data = Log-transformed data - mean (Log-
transformed control)
Student T-test was used to statistically compare 
the fold change value of each group, with a and p < 0.05 
considered as significantly different. All samples showing 
efficiency with less than 80% of amplification, weak 
amplification curves, with clinical issues (ex: glaucoma, 
eye medical treatment,) or outliers (http://graphpad.com/
quickcalcs/Grubbs1.cfm) were excluded of the analysis.
miR-associated SNP analysis
Data sources & subjects
We used public-access results from the National 
Eye Institute-supported AMD Gene Consortium (AGC) 
[22] to address our aims. In 2013 the AGC published 
findings from a large-scale multi-center genome-wide 
study on the molecular genetics of AMD (http://nih.gov/
news/health/mar2013/nei-03.htm). All AGC research 
was conducted according to the principles expressed in 
the Declaration of Helsinki and was initiated only after 
approval by institutional review boards (IRB) in each 
of the 18 participating centers. Informed consent was 
obtained from all participants. Details of human subject 
procedures, IRB approvals, and references to consenting 
processes exist at: http://www.nature.com/ng/journal/v45/
n4/extref/ng.2578-S1.pdf — pp. 30—41. All AGC data 
have been de-identified. 
The analytic sample contained > 4450 people with 
NV AMD and > 40,000 age- and sex-matched AMD-free 
controls of European and Asian ancestry. All findings 
passed quality assessment tests for completeness of 
genotyping and Hardy-Weinberg equilibrium. Details on 
methods and quality control procedures exist in Fritsche 
et al.[22] 
Regions of interest
Gene annotations and positional coordinates for 
genes encoding hsa-miR-146a-5p, hsa-miR-106b-5p, hsa-
miR-152-3p, and their target motifs were obtained with 
the Ensembl 80 database (21 March 2015, GRCh38.p2, 
http://useast.ensembl.org/index.html) via an interface 
to TarBase7 (http://diana.imis.athena-innovation.gr/
DianaTools/) in the Regulation 80 utility. Lists of genes 
encoding miRNA targets that have been validated with 
luciferase reporter assays, qPCR, and Western blots were 
assembled for each of the 3 miRNAs from TarBase 7 
(http://diana.imis.athena-innovation.gr/DianaTools/index.
php?r = tarbase/index) and miRTarBase (http://mirtarbase.
mbc.nctu.edu.tw/) - in some cases positional coordinates 
of miRNA motif-encoding areas were not available. 
Computational evidence on location of hsa-miR-146a-5p, 
hsa-miR-106b-5p, and hsa-miR-152-3p motif-encoding 
regions was obtained with microT-CDS ((http://diana.imis.
athena-innovation.gr/DianaTools/), applying a threshold of 
greater > 0.70 for strong prediction) and miRDB ((http://
mirdb.org/miRDB/), applying a Target Score threshold > 
80). We used HaploReg v3 (http://www.broadinstitute.org/
mammals/haploreg/haploreg_v3.php) with data from the 
1000 Genomes Project to identify co-inherited loci (R2 > 
0.80, EUR cohort as reference) as valid proxy measures 
in cases that SNPs in miRNA target motif regions were 
not present in the gene chip feature set reported by AGC. 
The Ingenuity Pathway Analysis knowledge base (June 
2015 version) was used to identify genes in which DNA 
sequence or DNA sequence products have been implicated 
to affect or to be affected by hsa-miR-146a-5p, hsa-miR-
106b-5p, or hsa-miR-152-3p. 
Data analysis
In Phase 1 we annotated and enumerated aspects 
of genomic regions of interest - these included positional 
coordinates of motif-encoding regions, resident genes, and 
DNA sequence variants within the encoding regions. The 
next step (Phase 2) was to assess putative differences in 
allelic frequencies in miRNA target-encoding loci between 
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people with NV AMD and their age- and sex-matched 
peers. The AGC probe set was not optimized for such 
purposes and thus we elected to also examine findings in 
all other loci in target-encoding genes (Phase 3) for the 
purpose of determining which NV AMD-associated genes 
may be the most promising candidates for focused work 
on miRNA target-encoding regions. 
NV AMD-gene relationships were analyzed in 
Phases 2 and 3 from AGC data using findings from 
additive models adjusted for population stratification.[22] 
In Phase 2, inferences were based an alpha-level of 0.05 
and adjusted by the number of tested SNPs in each motif-
encoding region (P = 0.05/(N)1/2). In Phase 3 we evaluated 
findings in regions of interest with Bonferroni-adjusted 
P-values and Q-values (Q-values were computed with 
QValue software package (www.genomics.princeton.edu/
storeylab/qvalue)). 
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